Tag - influenza vaccines

GHP News Latest Science

Literature update ViVa week 38-2026

1. Three doses help—but immunosuppressed patients remain a COVID-19 high-risk group Summary: In a systematic review and random-effects meta-analysis, Stadler and colleagues searched PubMed, Scopus, and Embase through...

23 September, 2026

12 min read

Latest Science

Feature: The 2026 vaccine licenses: influenza drives a new platform era

The most revealing feature of vaccine licensure in 2026 is not a newly targeted pathogen. It is the concentration of innovation around familiar respiratory threats: seasonal influenza and COVID-19. Four notable...

23 September, 2026

11 min read

Latest Science

ViVa 37 Feature: Influenza vaccines for the 2026–2027 respiratory season

For decades, seasonal influenza vaccines were produced primarily in embryonated eggs. Live attenuated influenza vaccine (LAIV), administered intranasally, became available in 2003. Over the past decade, additional...

16 September, 2026

11 min read

GHP News Outbreak Countries

ViVa News — Week 26

Over the last week (≈23–29 June 2026), only a few jurisdictions and agencies released materially new vaccine guidance, with meaningful activity centered on COVID‑19 adult booster policy (Canada, Australia, New Zealand)...

1 July, 2026

6 min read